AU2002329450A1 - Fragements of heat shock proteins and their use - Google Patents

Fragements of heat shock proteins and their use

Info

Publication number
AU2002329450A1
AU2002329450A1 AU2002329450A AU2002329450A AU2002329450A1 AU 2002329450 A1 AU2002329450 A1 AU 2002329450A1 AU 2002329450 A AU2002329450 A AU 2002329450A AU 2002329450 A AU2002329450 A AU 2002329450A AU 2002329450 A1 AU2002329450 A1 AU 2002329450A1
Authority
AU
Australia
Prior art keywords
fragements
heat shock
shock proteins
proteins
heat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002329450A
Other languages
English (en)
Inventor
Charles George Kelly
Thomas Lehner
Mahavir Singh
Yufei Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
King's College London
Original Assignee
King's College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King's College London filed Critical King's College London
Publication of AU2002329450A1 publication Critical patent/AU2002329450A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002329450A 2001-10-03 2002-10-03 Fragements of heat shock proteins and their use Abandoned AU2002329450A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0123756.9 2001-10-03
GBGB0123756.9A GB0123756D0 (en) 2001-10-03 2001-10-03 A novel chaperone-type of adjuvant for vaccination - Basic 1
PCT/GB2002/004475 WO2003029289A2 (en) 2001-10-03 2002-10-03 Fragements of heat shock proteins and their use

Publications (1)

Publication Number Publication Date
AU2002329450A1 true AU2002329450A1 (en) 2003-04-14

Family

ID=9923176

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002329450A Abandoned AU2002329450A1 (en) 2001-10-03 2002-10-03 Fragements of heat shock proteins and their use

Country Status (7)

Country Link
US (1) US20060264609A1 (enExample)
EP (1) EP1434794A2 (enExample)
JP (1) JP2005512518A (enExample)
AU (1) AU2002329450A1 (enExample)
CA (1) CA2463404A1 (enExample)
GB (1) GB0123756D0 (enExample)
WO (1) WO2003029289A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101151049A (zh) * 2004-06-15 2008-03-26 纽约血液中心有限公司 旋盘尾丝虫的天然产物的佐剂和免疫加强性能
US20090118173A1 (en) * 2006-01-24 2009-05-07 Universiteit Utrecht Uu Holding B.V. Treatment and prevention of inflammatory bowel diseases
CN101801402B (zh) * 2007-07-06 2013-08-28 乌得勒支大学控股有限公司 炎性疾病和自身免疫疾病的治疗和预防
JP5616336B2 (ja) 2008-06-26 2014-10-29 オルファザイム エーピーエスＯｒｐｈａｚｙｍｅ Ａｐｓ 酵素活性の調節因子としてのＨｓｐ７０の使用
CA2804501C (en) 2010-07-06 2021-01-26 Novartis Ag Noro virus derived immunogenic compositions and methods
US9662375B2 (en) 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
US10709700B2 (en) 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
US20170260286A1 (en) * 2016-03-10 2017-09-14 The General Hospital Corporation Antigen-Binding Fusion Proteins with Modified HSP70 Domains
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
ES2831764T3 (es) 2016-04-29 2021-06-09 Orphazyme As Arimoclomol para el tratamiento de trastornos asociados a glucocerebrosidasa
WO2018049118A1 (en) * 2016-09-09 2018-03-15 The General Hospital Corporation Hsp fusion protein with anti-chemorepellant agent for treatment of cancer
AU2021357131A1 (en) * 2020-10-09 2023-05-25 Zeria Pharmaceutical Co., Ltd. Novel use of mycobacterium tuberculosis extract
EP4247792A1 (en) 2020-11-19 2023-09-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777890B1 (fr) * 1998-04-22 2000-12-29 Roussy Inst Gustave Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer
DE60038622D1 (de) * 1999-10-20 2008-05-29 Univ Johns Hopkins Med Chimäre immunogene zusammensetzungen und dafür kodierende nukleinsäure
GB9930443D0 (en) * 1999-12-22 2000-02-16 King S College London Novel use of heat shock proteins
EP1209226A3 (en) * 2000-11-07 2002-06-05 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70)
WO2002061113A2 (en) * 2001-02-01 2002-08-08 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation

Also Published As

Publication number Publication date
JP2005512518A (ja) 2005-05-12
WO2003029289A3 (en) 2003-08-28
CA2463404A1 (en) 2003-04-10
GB0123756D0 (en) 2001-11-21
EP1434794A2 (en) 2004-07-07
US20060264609A1 (en) 2006-11-23
WO2003029289A2 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
ZA200305825B (en) Modified antibodies and methods of use
AU2002258790A1 (en) Novel microarrays and methods of use thereof
GB2373565B (en) Detonation transfer subassembly and method for use of the same
WO2003059257A8 (en) Anti-angiogenic proteins and fragmentsand methods of use thereof
AU2001278076A1 (en) Bstp-5 proteins and related reagents and methods of use thereof
EP1435911A4 (en) PRODUCTS WITH PROTEIN MATRIX MATERIALS AND METHOD FOR THEIR PRODUCTION AND USE
AU2002314466A1 (en) Withasol and methods of use
AU2002250098A1 (en) Phosphoprotein binding agents and methods of their use
AU2002326751A1 (en) Immunoglobulin e vaccines and methods of use thereof
AU2002251999A1 (en) Methods and compositions for the construction and use of fusion libraries using computational protein design methods
AU2207301A (en) Use of heat shock proteins
AU2001248277A1 (en) Shock heat treatment of polypeptides
AU2002363938A1 (en) Methods and use of motoneuronotropic factors
AU2002341828A1 (en) Enhanced proteins and methods for their use
AU3230500A (en) Isolation and characterization of heat shock protein
AUPR595601A0 (en) Hypoglycaemic peptides and methods of use thereof
IL150113A0 (en) Fragments and antagonists of heat shock protein 60
AU2002217895A1 (en) Inducing expression of heat shock proteins
AU2001285814A1 (en) Use of the heat shock protein gp96
AU2002360303A1 (en) Novel histone methyltransferase and methods of its use
AU2002352698A1 (en) Immune-related proteins and the regulation of the same
AU2002357609A1 (en) Novel proteins and dnas thereof
AU2002231486A1 (en) Chlamydia heat shock protein
GB9817226D0 (en) Novel use of heat shock proteins
AU2002318582A1 (en) Synthesis and functin inhibitors for heat shock proteins

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase